Indianapolis-based Lilly, the 12th largest employer in Indiana with 10,600 workers in the state, said it didn’t have a specific timeline for how long the precaution would last.
Read MoreState officials have taken sharp criticism in the last week for the slow pace of testing. Through Tuesday, the Indiana State Department of Health had conducted 193 tests, out of which 39 were presumed positive.
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
Executives at Eli Lilly and Co. are telling investors the worst is behind the company and only good things await. But the drugmaker still has a few things to prove.
Eli Lilly and Co. CEO John Lechleiter told Wall Street analysts recently that, while there have been “individual huge drug price increases,” the overall cost of drugs is rising very slowly and remains a small part of overall U.S. health care spending.
The safety-net hospital system in Indianapolis will create the Center for Brain Care Innovation and try to use telemedicine and a digital avatar to reach as many as 150,000 Hoosiers and 10 million patients outside Indiana by 2030.
Patients’ anger over high deductibles and high drug prices is spurring presidential candidates to respond—even as the actual prices of health care services are growing slower than at any time since 1990.
It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.
Eli Lilly and Co. didn’t win approval for a new drug last week. But its latest study of an existing diabetes drug could create a blockbuster in its own right—adding as much as $1 billion a year to the coffers of the Indianapolis-based drugmaker.
Hoosier entrepreneurs in health care and life sciences attracted more than $31 million from investors during the first half of the year. But too few Indiana companies have developed their technology enough to attract venture capitalists or tap stock markets.
State and city leaders spend millions each year to entice companies to move here and add jobs here. But for the second time in three months, Eli Lilly and Co. has shown that the biggest attraction to a company is talented workers.
The CEOs of Eli Lilly and Anthem are being rewarded by investors for taking high-risk approaches to develop breakthrough drugs, make major acquisitions.
The Indianapolis-based drugmaker on Wednesday will release new data from patients taking its Alzheimer’s drug that could show whether the drug has slowed the progression of their disease. That will show investors whether the 45 percent rise in Lilly’s stock price over the past year is justified.
Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.
Lilly’s basal insulin peglispro proved more effective than the $7 billion blockbuster Lantus at controlling diabetics’ blood sugar, but it also had greater effect on patients’ livers and hearts. Analysts are unsure of its future.
The fact that Assembly Biosciences Inc. and AgeneBio now list New York and Baltimore, respectively, as their headquarters cities doesn’t hurt Indiana and could help the state, says David Johnson, CEO of BioCrossroads.
New research shows patients lose trust and confidence in doctors that take money for travel, but like it when their doctors are paid as consultants during the development of new products.
Top-down culture change only works in North Korea, says the head of a group of local CEOs that is working broadly and subtly, not tyrannically, to improve Indy’s culture of eating and exercising.
The CEOs of Anthem, Lilly, Zimmer and Hill-Rom tried to woo investors at the J.P. Morgan Healthcare conference by stressing how they’re broadening business beyond plain-old insurance, pharmaceuticals, implants and hospital beds.
Since Obamcare was expected to boost insurance coverage nationally by 32 million people, drugmakers like Eli Lilly and Co. stood to benefit. But it’s not working out that way. At least not for Lilly.
On Obamacare, the new Republican-controlled Congress should “leave the façade of the building and then demolish the inside of it,” according to one GOP leader. If Republicans take that approach, here are four things that could change in the next two years.
